Prolonged olanzapine treatment reduces the risk of psychotic depression relapse
KEY POINT
Continuing olanzapine treatment in patients with psychotic depression who were in remission reduced the risk of psychotic depression relapse compared with stopping therapy, according to a study published in JAMA. However, metabolic adverse events are increased in those who continue treatment, the study showed.
SOURCES
Flint AJ, et al. Effect of continuing olanzapine vs placebo on relapse among patients with psychotic depression in remission: The STOP-PD II randomized clinical trial. JAMA. 2019;322(7):622–31.
Coryell WH. Maintenance treatment for psychotic depressive disorders: Progress and remaining challenges. JAMA. 2019;322(7):615–7.
